Teva, Baxter continue to appeal $500M verdict in US hepatitis C propofol case
This article was originally published in Scrip
Executive Summary
A unit of Teva Pharmaceutical Industries and Baxter Healthcare continue with an appeal to the Supreme Court of the State of Nevada seeking to overturn a $500 million punitive damages award of 2010 to a Nevada man who contracted hepatitis C during an endoscopic procedure which involved the anaesthetic propofol. The companies claim in essence they were not given a fair shake, and were precluded during the trial of presenting any defence.